Table 1 Baseline characteristics of patients (N = 48).

From: Prediction of lung cancer using novel biomarkers based on microbiome profiling of bronchoalveolar lavage fluid

Variable

Patients with lung cancer (N = 24)

Patients with benign lung diseases (N = 24)

P-value

Age, years

67.7 ± 9.7

64.7 ± 9.4

0.276

BMI

21.6 ± 3.6

22.3 ± 4.8

0.547

Sex

 Male

20 (83.3)

17 (70.8)

0.494

 Female

4 (16.7)

7 (29.2)

Smoking status

 Never

5 (20.8)

11 (45.8)

0.125

 Former/current

19 (79.2)

13 (54.2)

Histology

 Adenocarcinoma

7 (29.2)

  

 Squamous

13 (54.2)

  

 Small cell carcinoma

4 (16.7)

  

EGFR

 Mutant

2 (8.3)

  

 Wild type

22 (91.7)

  

PD-L1 expression†

 Unknown

3 (12.5)

  

 No/low (TPS 0–49%)

14 (58.3)

  

 High (TPS ≥ 50%)

7 (29.2)

  

Stage

 III

10 (41.7)

  

 IV

14 (58.3)

  

Benign lung disease

 Pneumonia

 

11 (45.8)

 

 Lung nodule

 

1 (4.2)

 

 Anthracofibrosis

 

2 (8.3)

 

 Bronchiectasis

 

3 (12.5)

 

 Bronchitis

 

2 (8.3)

 

 Interstitial lung disease

 

1 (4.2)

 

 Others

 

4 (16.7)

 
  1. EGFR epidermal growth factor receptor, PD-L1 programmed death-ligand 1, TPS tumor proportion score.
  2. †The classification of subgroups according to PD-L1 expression was based on the results of the 22C3 pharmDx assay, and patients without 22C3 pharmDx assay results were classified based on the SP263 assay.
Back to article page